- MGI Announces Price and Early Access Customer of MGISEQ-T7
- MGI Announces Milestone of 1,000 Sequencers Installed and Opens Early Access Program for Groundbreaking Ultra-High-Throughput Sequencer, MGISEQ-T7
- Three BGI Researchers Listed as Highly Cited Researchers
- China National GeneBank and Macquarie University Deepen Cooperation in Synthetic Biology
- Establishment of the first Macaca fascicularis gut microbiome gene catalog
- Establishing the first gene catalogue of Sprague-Dawley rat gut metagenome based on the BGISEQ-500 platform
- The international Sc2.0 Project is on track to build the world’s first synthetic yeast genome
- Avian-specific conserved genomic elements play important regulatory roles in the macroevolution of avian-specific features
- Leading Health Organizations in Canada and China Teaming up to Accelerate Precision Medicine
- World’s largest genomic organisation to collaborate with leading Queensland researchers
- Ranomics Partners with BGI to Classify Variants of Unknown Significance
- BGI and UW collaborate on precision medicine development
- Meet The Chinese Company That Wants To Be The Intel Of Personalized Medicine
- Chinese innovation : BGI’s code for success
- Prof. Huanming Yang to Receive Membership from Royal Danish Academy of Sciences and Letters
- UW, Chinese genomics group forge new partnership to advance biomedical research
Tel: +86-755-36307212Email: email@example.com
SEATTLE, WA, November 6, 2018 – BGI, a global genomics company, and Fred Hutchinson Cancer Research Center (Fred Hutch), a world-renowned nonprofit research institute, have signed a Memorandum of Understanding (MOU) to discuss and explore collaborative projects in the field of genomics, with the goal of advancing research and educational opportunities and improving the health of people around the world.
Cancer is increasingly recognized as a health threat to individuals in both resource-rich countries and low- and middle-income countries. Through advances in next-generation sequencing (NGS), analyzing DNA can improve early cancer detection and diagnosis and optimize treatment plans.
The new MOU, signed by Dr. Jian Wang, chairman and co-founder of BGI and Dr. Gary Gilliland, president and director of Fred Hutch, provides a framework to support mutually agreeable projects in a range of research areas, including cancer genomics, immunology and infectious disease studies. These potential collaborative projects will benefit from BGI’s proprietary sequencing technology and global network and the deep expertise of Fred Hutch in cancer research and analysis.
Dr. Gary Gilliland, President and Director of Fred Hutch (Left) and Dr. Jian Wang, Chairmanand Co-founder of BGI Signs MOU
BGI and Fred Hutch also plan to discuss and explore building capacity and establishing partnerships with hospitals and research institutions in China and Africa. Preliminarily, the two organizations have discussed collaborating with hospitals in the Shenzhen area, where BGI is headquartered, and supporting the work of Fred Hutch in its collaboration with Uganda Cancer Institute,a comprehensive cancer facility that serves a five-country region with a total population of more than 100 million.
BGI provides a wide range of next generation sequencing services and a broad portfolio of genetic tests for medical institutions, research intuitions, and other public and private partners, with a mission to advance life science research and expand access to genomics for the benefit of humanity.
“We look forward to exploring and working with BGI on many important research projects, with the shared goal of ensuring that more people around the world can benefit from new discoveries and better treatments,” said Dr. Edus Houston Warren, head of Global Oncology at Fred Hutch.
“We are very fortunate to have an outstanding institution like Fred Hutch as a partner of BGI,” said Dr. Jian Wang, who first got to know Fred Hutch during his time as a research fellow at the University of Washington in the 1990s. “With the signing of this MOU, we are looking forward to working together closely to accelerate breakthroughs and improve people’s health and well-being, not only in the US and China but around the world.”
About Fred Hutchinson Cancer Research Center:
The Center was established in 1975 by Seattle surgeon Dr. William Hutchinson. Teams of world-renowned scientists and humanitarians at Fred Hutch work together to prevent, diagnose and treat cancer, HIV/AIDS, and other diseases.
BGI was founded in 1999 with the vision of using genomics to benefit mankind and has since become one of the largest genomics organizations in the world. With a focus on research and applications in the healthcare, pharmaceutical, conservation and environmental fields, BGI has a proven track record of innovative, high profile research that has generated over 1,600 publications. BGI’s goal is to make state-of-the-art genomics highly accessible to the global research community and clinical markets by integrating the industry’s broadest array of leading technologies, including BGI's own sequencing platform, economies of scale, and expert bioinformatics resources. BGI also offers a wide portfolio of transformative genetic testing products across major diseases, enabling medical providers and patients worldwide to realize the promise of genomics-based diagnostics and personalized healthcare.
Kristi Heim, BGI Deputy Director of Communications